Advanced search
Publication Cover
Current Medical Research and Opinion Volume 38, 2022 - Issue 10
Submit an article Journal homepage
3,566
Views
5
CrossRef citations to date
0
Altmetric
Hematology

A real-world study comparing pre-post billed annualized bleed rates and total cost of care among non-inhibitor patients with hemophilia A switching from FVIII prophylaxis to emicizumab

Katharine Batta Department of Hematology and Medical Oncology, Wake Forest Baptist School of Medicine, Winston-Salem, NC, USAORCID Iconhttps://orcid.org/0000-0003-3672-8741
ORCID Icon,
Bob G. Schultzb Outcomes Research, Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, USAORCID Iconhttps://orcid.org/0000-0002-7023-8378
ORCID Icon,
Jorge Caicedob Outcomes Research, Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, USAORCID Iconhttps://orcid.org/0000-0002-5816-568X
ORCID Icon,
Christopher S. Hollenbeakc Department of Health Policy and Administration, The Pennsylvania State University, College of Health and Human Development, University Park, PA, USAORCID Iconhttps://orcid.org/0000-0002-3362-814X
ORCID Icon,
Neha Agrawald Complete HEOR Solutions, North Wales, PA, USAORCID Iconhttps://orcid.org/0000-0002-1758-2786
ORCID Icon,
Sagnik Chatterjeed Complete HEOR Solutions, North Wales, PA, USAORCID Iconhttps://orcid.org/0000-0002-8800-7746
ORCID Icon &
Michael Bullanob Outcomes Research, Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-9961-4576
ORCID Icon show all
Pages 1685-1693 | Received 24 Jun 2022, Accepted 19 Jul 2022, Published online: 03 Aug 2022

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Roberto Lúcio Muniz, Ricardo Mesquita Camelo, Maiara Silva Araújo, Mariana Michel Barbosa, Augusto Afonso Guerra, Francisco de Assis Acurcio & Juliana Alvares-Teodoro. (2023) Efficacy/effectiveness and safety of emicizumab prophylaxis of people with hemophilia A: a systematic review and meta-analysis. Expert Review of Hematology 16:12, pages 1087-1097.
Read now
Miguel Escobar, Michael Bullano, Ali G. Mokdad, Jorge Caicedo, Bob G. Schultz, Qi Fan & Sumit Verma. (2023) A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors. Expert Review of Hematology 16:6, pages 467-474.
Read now
Maryia Zhdanava, Jacqueline Pesa, Porpong Boonmak, Qian Cai, Dominic Pilon, Zia Choudhry & Nizar Souayah. Economic burden of generalized myasthenia gravis (MG) in the United States and the impact of common comorbidities and acute MG- events. Current Medical Research and Opinion 0:0, pages 1-12.
Read now

Articles from other publishers (2)

Konrad van der Zwet, Marloes de Kovel, Jayashree Motwani, Chris van Geet, Beatrice Nolan, Heidi Glosli, Carmen Escuriola Ettingshausen, Christoph Königs, Gili Kenet & Kathelijn Fischer. (2024) Bleeding control improves after switching to emicizumab: Real‐world experience of 177 children in the PedNet registry. Haemophilia 30:3, pages 685-692.
Crossref
Jan Astermark, Tyler W Buckner, Laurent Frenzel, Anthony J Hatswell, Xiaojun You, Hai Liu, Erin Goodman, Sandra Santos, Charles Hawes, David Hinds & Robert Klamroth. (2023) Matching‐adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis. Haemophilia 29:4, pages 1087-1094.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.